Roche Diagnostics Gmbh

Klasu Muhlegger

Herbert Von Der Eltz

Frank Seela

Helmut Rosemeyer

Oligodeoxyribonucleotides in which at least two 2&prime;-deoxy-&bgr;-D-erythro-pentofuranosyl groups are replaced by 2&prime;-deoxy-&bgr;-D-threo-pentofuranosyl groups at both the 5&prime; end and 3&prime; end, and oligodeoxyribonucleotides in which at least 20% of the 2&prime;-deoxy-&bgr;-D-erythro-pentofuranosyl groups in consecutive nucleotide building blocks are replaced by 2&prime;-deoxy-&bgr;-D-threo-pentofuranosyl groups and which are composed of 6 to 100 nucleotide building blocks, are suitable for the inhibition of the expression of viral genes and oncogenes by the antisense principle and can be used for the production of pharmaceutical agents with antiviral activity.

Growing community of inventors

Polling, Germany

Klasu Muhlegger